抑癌基因p16重组兔单抗

Rrmab®兔单抗
2026-01-04~2026-02-28,RR26012026-01-04~2026-02-28,TR
抑癌基因p16重组兔单抗
货号:bsm-63048R
产品详情
相关标记
相关产品
相关文献
常见问题

概述

产品编号
bsm-63048R
产品类型
重组兔单抗、mIHC精品抗体
英文名称
CDKN2A/p16-INK4a Recombinant Rabbit mAb
中文名称
抑癌基因p16重组兔单抗
英文别名
ARF; CAI2; CDK4I; CDKN2; CMM2; INK4; INK4A; MLM; MTS-1; MTS1; P14; P14ARF; P16; P16-INK4A; P16INK4; P16INK4A; P19; P19ARF; TP16; ARF-INK4a; INK4a-ARF; Ink4a/Arf; Pctr1; p16(INK4a); p19; p16Cdkn2a; CDN2A_HUMAN; CDKN2A; Cyclin-dependent kinase 4 inhibitor A (CDK4I); Multiple tumor suppressor 1 (MTS-1); p16-INK4a (p16-INK4 | p16INK4A); CDN2A_MOUSE; p16-INK4a (p16-INK4); CDN2A_RAT; p16-INK4a (p16 | p16-INK4);
抗体来源
Rabbit
免疫原
A synthesized peptide derived from human CDKN2A: 120-156/156
亚型
IgG
性状
Liquid
纯化方法
affinity purified by Protein A
克隆类型
Recombinant
克隆号
14E19
理论分子量
17 kDa
储存液
10mM phosphate buffered saline , pH 7.4, 150mM sodium chloride, 0.05% BSA, 0.02% Proclin300 and 50% glycerol.
SWISS
Gene ID
保存条件
Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles.
注意事项
This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
产品介绍
p16主要功能是通过抑制CDK4而阻止细胞由G1期进入S期,使细胞增殖受到限制。用于各种恶性肿瘤如肺癌、恶黑、乳腺癌的研究。目前的研究细胞周期依赖激酶抑制p16INK4a蛋白在宫颈上皮内病变(CIN)中作为一个新标记物. p16INK4a的过表达与HPV E7区(病毒早期蛋白即病毒致癌基因编码区)活性有密切相关性。 p16/CDKN2基因是新近发现的肿瘤抑制基因,已有研究表明该基因在许多肿瘤出现缺失、突变或重排现象.
背景资料
This gene generates several transcript variants which differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene; this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, the E3 ubiquitin-protein ligase MDM2, a protein responsible for the degradation of p53. In spite of the structural and functional differences, the CDK inhibitor isoforms and the ARF product encoded by this gene, through the regulatory roles of CDK4 and p53 in cell cycle G1 progression, share a common functionality in cell cycle G1 control. This gene is frequently mutated or deleted in a wide variety of tumors, and is known to be an important tumor suppressor gene. [provided by RefSeq, Sep 2012]
抑癌基因p16重组兔单抗抑癌基因p16重组兔单抗抑癌基因p16重组兔单抗抑癌基因p16重组兔单抗抑癌基因p16重组兔单抗抑癌基因p16重组兔单抗

产品应用

应用已检合格种属预测种属推荐稀释比例
WBHuman1:500-2000
IHC-PHuman1:100-500
IHC-FHuman1:100-500
IFHuman1:100-500
ICC/IFHuman1:50-200

交叉反应

交叉反应: Human

相关产品

暂无相关产品

靶标

基因名
Cdkn2a
蛋白名
Tumor suppressor ARF
亚基
Heterodimer with CDK4 or CDK6. Predominant p16 complexes contained CDK6. Interacts (isoforms 1,2 and 4) with CDK4 (both 'T-172'-phosphorylated and non-phosphorylated forms); the interaction inhibits cyclin D-CDK4 kinase activity. Interacts with ISCO2.
亚细胞定位
Cytoplasm. Nucleus.
组织特异性
Widely expressed but not detected in brain or skeletal muscle. Isoform 3 is pancreas-specific.
翻译后修饰
Ubiquitinated in normal cells by TRIP12 via the ubiquitin fusion degradation (UFD) pathway, a process that mediates ubiquitination at the N-terminus, regardeless of the absence of lysine residues. Ubiquitination leads to its degradation. In cancer cells, however, TRIP12 is located in a different cell compartment, preventing ubiquitination and degradation.
疾病
Note=The association between cutaneous and uveal melanomas in some families suggests that mutations in CDKN2A may account for a proportion of uveal melanomas. However, CDKN2A mutations are rarely found in uveal melanoma patients.
Defects in CDKN2A are the cause of cutaneous malignant melanoma type 2 (CMM2) [MIM:155601]. Malignant melanoma is a malignant neoplasm of melanocytes, arising de novo or from a pre-existing benign nevus, which occurs most often in the skin but also may involve other sites.
Defects in CDKN2A are the cause of familial atypical multiple mole melanoma-pancreatic carcinoma syndrome (FAMMMPC) [MIM:606719].
Defects in CDKN2A are a cause of Li-Fraumeni syndrome (LFS) [MIM:151623]. LFS is a highly penetrant familial cancer phenotype usually associated with inherited mutations in TP53. [DISEASE] Defects in CDKN2A are the cause of melanoma-astrocytoma syndrome (MASTS) [MIM:155755]. The melanoma-astrocytoma syndrome is characterized by a dual predisposition to melanoma and neural system tumors, commonly astrocytoma.
相似性
Belongs to the CDKN2 cyclin-dependent kinase inhibitor family.
Contains 4 ANK repeats.
功能
Acts as a negative regulator of the proliferation of normal cells by interacting strongly with CDK4 and CDK6. This inhibits their ability to interact with cyclins D and to phosphorylate the retinoblastoma protein.

标记抗体

暂无标记数据

同靶标产品

暂无同靶标产品

相关文献

提示: 发表研究结果有使用 bsm-63048R 时请让我们知道,以便我们可以引用参考文章。作为回馈,资料提供者将获得我们送上的小礼品。
具体参考文献:bsm-63048R 被引用于1文献中

暂无相关文献

常见问题

暂无常见问题